A Study Comparing the Dulaglutide Pen and the Semaglutide Pen

NCT03724981 on ClinicalTrials.gov · last registry update 2020-04-24

An unusually large phase 4: 312 participants, more than double the 75 typical for the stage. The sponsor logged completion for 12 April 2019. Primary outcome, as filed: Participant Preference Between 2 Injection Devices Based on Global Preference Item. semaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P4
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Eli Lilly and Company
Sponsor type: Industry
Enrollment: 312
Started: 2018-10-18
Primary completion: 2019-04-12 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Participant Preference Between 2 Injection Devices Based on Global Preference Item

Conditions studied

Diabetes Mellitus, Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.